Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action.
about
The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior.Rhythm and blues: animal models of epilepsy and depression comorbidity.Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in miceReduced levels of NR1 and NR2A with depression-like behavior in different brain regions in prenatally stressed juvenile offspring.Assessing the neuronal serotonergic target-based antidepressant stratagem: impact of in vivo interaction studies and knockout modelsAre vesicular neurotransmitter transporters potential treatment targets for temporal lobe epilepsy?mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?Pharmacokinetic/pharmacodynamic considerations for epilepsy - depression comorbidities.In vivo brain microdialysis as a formulation-screening tool for a poorly soluble centrally acting drug.Negative versus positive allosteric modulation of metabotropic glutamate receptors (mGluR5): indices for potential pro-cognitive drug properties based on EEG network oscillations and sleep-wake organization in rats.Altered expression of vesicular monoamine transporter 2 in epileptic patients and experimental rats.5-hydroxytryptamine1A receptor density in the hippocampus of patients with temporal lobe epilepsy is associated with disease duration.Effects of oxcarbazepine on monoamines content in hippocampus and head and body shakes and sleep patterns in kainic acid-treated rats.Increased hippocampal noradrenaline is a biomarker for efficacy of vagus nerve stimulation in a limbic seizure model.The Impact and Mechanism of Methylated Metabotropic Glutamate Receptors 1 and 5 in the Hippocampus on Depression-Like Behavior in Prenatal Stress Offspring Rats.
P2860
Q33706833-D15C6E22-042C-4A89-B74E-9E34C5E43E9EQ33974889-57121AD2-2DFB-4CCF-A7C8-8F621DBE95ADQ34770846-4E2409F9-4F24-41F2-9039-63C1795497F0Q35054086-31AB9427-06F5-46DB-B712-2654DC22CE81Q37206280-A75DAD97-7232-4F46-BADE-B61F4A6D0772Q38134724-33C1A4DB-449C-4468-A152-B988CF2C417AQ38747119-F2289EAA-52E9-48C1-BD73-7440B769DC61Q38856602-B0B0BEAE-F5AD-4115-9CCA-7CB1069C835FQ46646546-4564AA53-2F3C-4E6A-B6DB-726B5B57EF77Q48022620-1FAA81AD-FE91-4584-84E3-2CA790DB8FC8Q48121473-33376F31-18D5-4A76-9466-4DF5AD180AE2Q48250322-C6B2A279-B54E-47B6-AFF4-DEC4BFB5D53AQ48291619-4074A74E-4793-4F54-B6D6-E2FEE447ABE0Q49072157-1382B0E1-0811-45CB-A258-F79524F3E7A9Q55497134-C4348DBE-BCFC-4D14-A2B7-90BD9FEDE9A9
P2860
Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Direct enhancement of hippocam ...... ressant-anticonvulsant action.
@en
Direct enhancement of hippocam ...... ressant-anticonvulsant action.
@nl
type
label
Direct enhancement of hippocam ...... ressant-anticonvulsant action.
@en
Direct enhancement of hippocam ...... ressant-anticonvulsant action.
@nl
prefLabel
Direct enhancement of hippocam ...... ressant-anticonvulsant action.
@en
Direct enhancement of hippocam ...... ressant-anticonvulsant action.
@nl
P2093
P1433
P1476
Direct enhancement of hippocam ...... pressant-anticonvulsant action
@en
P2093
Alfred Meurs
Guy Ebinger
Ilse Smolders
Jeanelle Portelli
Ralph Clinckers
Yvette Michotte
P304
P356
10.1016/J.NEUROPHARM.2008.02.006
P577
2008-04-01T00:00:00Z